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Abstract
Background: To identify baseline/clinical characteristics associated with clinically meaningful responses to insulin
glargine 100 U/mL (IGlar) in insulin-naive people with type 2 diabetes mellitus (T2DM).
Methods: Individual participant data were pooled from 3 randomized trials to compare baseline characteristics and
clinical outcomes associated with 24-week response to IGlar in combination with non-insulin antihyperglycemic
agents in participants with T2DM. Responders were defined as achieving endpoint HbA1c target < 53 mmol/mol
(< 7%) and/or ≥ 11 mmol/mol (≥ 1%) HbA1c reduction from baseline.
Results: Differences in baseline characteristics for responders versus nonresponders were higher HbA1c (99 vs
91 mmol/mol [9.1 vs 8.3%]; P < 0.001), higher fasting blood glucose (FBG; 10.4 vs 8.8 mmol/L [187 vs 159 mg/dL;
P < 0.001), and fewer participants (94% vs 98%; P = 0.006) taking oral medications targeting postprandial blood
glucose (BG). Most participants (80%) achieved one or both components of composite endpoint. 12-week response
was a strong predictor of subsequent 24-week response (sensitivity, 85.9%; predictive positive value, 91.4%). At both
12 and 24 weeks, < 40% of responders and nonresponders reached target FBG ≤ 5.6 mmol/L (≤ 100 mg/dL).
Responders at 24 weeks had higher incidence of hypoglycemia (total, 82.5% vs 70.4%; P < 0.001; nocturnal, 60.3% vs
50.5%; P = 0.002; documented symptomatic, 65.8% vs 55.6%; P < 0.001) than nonresponders.
Conclusions: Baseline characteristics associated with response were identified. The strong predictability of 12-week
response suggests that the magnitude of early HbA1c reduction should be considered when assessing response to
IGlar. More aggressive IGlar titration may be reasonable for nonresponders and responders who have not reached
FBG and HbA1c targets, taking into account other BG timepoints.
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Background
Dual or triple therapy with insulin (usually a basal insulin)
in combination with metformin or other noninsulin anti-
hyperglycemic medication is recommended for people with
type 2 diabetes mellitus (T2DM) who do not attain gly-
cemic target on noninsulin antihyperglycemic medications
alone [1]. For people with newly diagnosed T2DM who are
symptomatic and/or have highly elevated levels of glycated
hemoglobin (HbA1c) (≥ 86 mmol/mol [≥ 10%]) and/or
blood glucose (BG) (≥ 16.7 mmol/L [≥ 300 mg/dL]), basal-
bolus insulin (preferred if symptomatic) or basal insulin
plus a glucagon-like peptide-1 receptor agonist (GLP1-RA)
should be considered for initial treatment [1]. Insulin glar-
gine 100 units/mL (IGlar) was the first basal insulin
analogue, which provided almost 24-h glycemic control
with once-daily injection and lower risk for nocturnal
hypoglycemia compared with human neutral protamine
Hagedorn insulin, while having similar efficacy in terms of
number of participants reaching HbA1c targets [2–6].
IGlar has since become a benchmark for the development
of novel basal insulin analogues [7]. These newer marketed
basal insulins, insulin degludec and insulin glargine
300 units/mL, are non-inferior to IGlar in terms of efficacy
and in certain subpopulations may provide some advan-
tages over IGlar, such as reduced nocturnal hypoglycemia,
as shown in some insulin degludec 100 units/mL studies
[8–10] and in insulin glargine 300 units/mL studies of par-
ticipants already receiving high-dose basal insulin [11, 12].
IGlar, however, remains an important option for the man-
agement of T2DM.
In recent years, guidelines and position statements
recommend that the choice of pharmacologic agents are
to be guided by a patient-centered approach that
considers factors like efficacy, hypoglycemia risk, and
impact on weight. Even though this method allows for
individualization of treatment based on several clinical
and social factors, it has become increasingly challenging
for healthcare providers to select from a plethora of anti-
hyperglycemic classes and furthermore from different
products within each class. Moreover, and specifically for
basal insulin, recent literature emphasized the importance
of proper titration before treatment intensification [13–15].
Anticipating treatment failures (e.g., minimal improve-
ments, frequent and/or severe hypoglycemia) and estab-
lishing realistic expectations of treatment with individuals
are important in clinical practice. To reach such decisions,
it would be helpful to understand the characteristics of
people with T2DM who do or do not respond to a com-
mon starter insulin, IGlar.
A few studies have investigated clinical characteristics
of people with diabetes on IGlar achieving a target
HbA1c of 53 mmol/mol (7%) [13–16]. These studies
showed that only a few baseline characteristics were
consistently associated with reaching target: lower
HbA1c at baseline and shorter duration of diabetes
[14, 16]. Furthermore, it was shown that as baseline
HbA1c increased, so did mean reduction in HbA1c from
baseline; however, progressively fewer participants achieved
target HbA1c at study endpoint with every 1% increase in
baseline HbA1c. Therefore, these studies were focused
mainly on whether patients reached target or not, with no
particular attention to patients who may have experienced
clinically significant reductions in HbA1c (albeit short of
reaching the HbA1c of 7%).
Recent analyses have shown that a composite
HbA1c measured by a decrease from baseline in
HbA1c of ≥ 11 mmol/mol (≥ 1%) and/or achievement of
HbA1c target < 53 mmol/mol (< 7%) identifies more pa-
tients with clinically meaningful responses to insulin ther-
apy than attainment of target HbA1c alone [17, 18].
Indeed, it has been shown that a decrease in the HbA1c
value of ≥11 mmol/mol (≥1%) may confer clinical benefit,
as demonstrated by the UK Prospective Diabetes Study:
every 11 mmol/mol (1%) reduction in mean HbA1c level
was associated with reductions of 21% for any diabetes-
related endpoint, 21% for diabetes-related deaths, 14% for
myocardial infarctions, and 37% for microvascular compli-
cations [19].
This current post hoc analysis was conducted using an
integrated database of prospective clinical studies of once-
daily IGlar treatment among insulin-naïve people with
T2DM. The aims of this analysis were two-fold: 1) to iden-
tify factors/characteristics of responders to once-daily
IGlar at 24 weeks, and 2) to assess the sensitivity and
specificity of this composite HbA1c response measure at
12 weeks in predicting response at 24 weeks. Re-
sponse was defined as a composite endpoint: achieving
HbA1c < 53 mmol/mol (< 7%) and/or a ≥ 11 mmol/mol
(≥ 1%) reduction in HbA1c from baseline. This defin-
ition of response has been previously studied [17, 18],
and therefore was selected for this analysis based on




Individual participant data from 2 randomized clinical trials
sponsored by Eli Lilly and Company [20, 21] and 1 ran-
domized trial sponsored by Eli Lilly and Company and
Boehringer Ingelheim [22] were used for meta-analyses.
These studies were identified by an exhaustive search of Eli
Lilly and Company’s integrated clinical trial database based
on the following inclusion criteria: 1) participants were
insulin-naïve with T2DM, 2) a sufficient number of partici-
pants received IGlar (Basaglar®/Abasaglar®, Boehringer
Ingelheim and Eli Lilly and Company, or Lantus®, Sanofi-
Aventis) for at least 24 weeks, and 3) IGlar was the only
insulin component in the antihyperglycemic treatment.
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Buse et al. [20] compared the efficacy and safety of
twice-daily (BID) insulin lispro mixture 75/25 and once-
daily (QD) IGlar in a randomized, open-label, 24-week,
non-inferiority trial conducted in 11 countries (Argentina,
Australia, Brazil, Canada, Greece, Hungary, India, the
Netherlands, Romania, Spain, and the United States).
Eligible participants were insulin-naïve adults ≥ 18 years
of age with T2DM and taking ≥ 2 oral antihyperglycemic
medications (OAMs). Jain et al. [21] compared the efficacy
and safety of 2 progressive insulin regimens, QD insulin
glargine plus insulin lispro administered up to 3 times
daily (TID) versus insulin lispro mixture 50/50 adminis-
tered up to TID, in a randomized, open-label, 36-week,
non-inferiority trial conducted in 9 countries (Australia,
Canada, France, Greece, India, Republic of Korea, Mexico,
Russian Federation, and Spain). Eligible participants were
insulin-naïve adults ≥ 18 years of age with T2DM and
taking ≥ 2 OAMs. Rosenstock et al. [22] compared the
efficacy and safety of 2 IGlar products, LY IGlar versus
Lantus®, in a phase 3, randomized, double-blind, 24-week,
non-inferiority trial conducted in 11 countries (Czech
Republic, France, Germany, Greece, Hungary, Italy, South
Korea, Mexico, Poland, Spain, and the United States). Eli-
gible participants were adults ≥ 18 years of age with
T2DM who were either insulin-naïve or previously on
Lantus® and taking ≥ 2 OAMs.
In each of these trials [20–22], postprandial glucose
(PPG) was collected through 7-Point self-monitored
blood glucose (SMBG) at weeks 0, 12, and 24 on 3 sep-
arate days in the 2-week period prior to each visit. Par-
ticipants were also given a diary to record hypoglycemia
events experienced throughout each study. For each
hypoglycemia episode, the participant was asked to rec-
ord the glucose value, if measured, and to describe the
treatment, including if the participant was able to self-
treat, and the outcome of the episode. At the onsite visit,
the investigator reviewed the diary with the participant to
verify and assess any need for treatment adjustment. Fur-
ther study design details and key outcomes from each trial
are summarized in Additional files 1 and 2, respectively.
Statistical analysis
Participants with non-missing HbA1c at 24 weeks were
analyzed and classified into 2 responder cohorts (yes vs
no) according to the composite HbA1c responder meas-
ure: HbA1c < 53 mmol/mol (< 7%) at 24 weeks or reduc-
tion in HbA1c from baseline to 24 weeks ≥ 11 mmol/mol
(≥ 1%). Responders were the participants who either
had HbA1c < 53 mmol/mol (< 7%) or had HbA1c re-
duction ≥ 11 mmol/mol (≥ 1%) at 24 weeks. Nonre-
sponders did not meet either criterion. For the 3 SMBG
profiles obtained at 0, 12, and 24 weeks, the average
SMBG value was used for analysis. Missing data at week
24 was expected due to the self-monitoring nature of
SMBG and the attrition throughout the trials. Overall,
about 60% of participants had non-missing PPG data at
week 24. More specifically, among the 1485 patients who
had non-missing HbA1c values at 24 weeks, 826 partici-
pants had non-missing glucose values post-breakfast and
post-midday meal and 829 participants had non-missing
post-dinner glucose at week 24. This was considered ad-
equate for analysis with the majority of participants con-
tributing data and a total sample size of > 800.
Heterogeneity across the studies was assessed by
study-by-responder interaction. P values for interaction
were nonsignificant for the majority of outcomes
measured indicating that results in these trials were
relatively homogeneous and therefore justified the
integration of these data. In 2 of the 3 studies analysed
[20, 22], responders had greater reductions in fasting
blood glucose (FBG) than nonresponders, while in the
3rd study [21], the 2 cohorts had similar reductions in
FBG, thereby resulting in a statistically significant
(P = 0.012) study-by-responder interaction (Additional file2).
Baseline participant characteristics and clinical pro-
files at 24 weeks (HbA1c, FBG, PPG, insulin dose,
and hypoglycemia categories [total hypoglycemia
(BG ≤ 3.9 mmol/L [≤ 70 mg/dL] or signs/symptoms), doc-
umented symptomatic (BG ≤ 3.9 mmol/L [≤ 70 mg/dL]
and signs/symptoms), nocturnal (between bedtime and
waking), and severe (required 3rd party assistance) were
compared between the responder cohorts. A 2-sided
P value of < 0.05 was considered statistically significant,
with P values based on the Pearson’s Chi-square test for
categorical variables and fixed effects meta-regression
model for continuous variables. Results presented are
model-adjusted mean and standard error (SE). Relation-
ships between improvements in glycemic outcomes as
continuous variables (FBG, daily mean PPG, and HbA1c)
and baseline variables (HbA1c, FBG), between improve-
ments in glycemic outcomes as continuous variables
(FBG, daily mean PPG, and HbA1c) and insulin dose, and
between hypoglycemic rate and insulin dose, were ex-
plored graphically using scatter plots as post hoc analyses.
Sensitivity, specificity, positive predictive value, and
negative predictive value were evaluated to assess if early
response at 12 weeks could predict subsequent response
at 24 weeks to support current guidelines that recom-
mend evaluation of therapeutic response to pharmaco-
logic interventions at 12 weeks after initiating therapy.
All analyses were performed using SAS Version 9.2®
or higher.
Results
Composite versus single HbA1c measure
The majority (80%) of participants achieved a meaning-
ful clinical reduction in HbA1c at 24 weeks, as defined
by the composite endpoint of attainment of target
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HbA1c < 53 mmol/mol (< 7%) and/or a ≥ 11 mmol/mol
(≥ 1%) decrease in HbA1c from baseline (Table 1). Of
those participants who responded to treatment, 50%
achieved both components of the composite HbA1c
endpoint, while 43% only experienced a ≥ 11 mmol/mol
(≥1%) decrease in HbA1c and 7% only reached target
HbA1c < 53 mmol/mol (< 7%). The composite HbA1c
endpoint identified 34% more responders than would
have been found by the single HbA1c endpoint, achieve-
ment of target HbA1c < 53 mmol/mol (< 7%), commonly
used in diabetes clinical studies.
Baseline characteristics of responders and nonresponders
The baseline characteristics of responders (N = 1188)
and nonresponders (N = 297) at 24 weeks were generally
similar; however, there were some notable differences
(Table 2). More men than women (54 vs 46%; P = 0.012)
responded to treatment. Responders also had higher
baseline HbA1c levels (mean, 9.1 vs 8.3% [99 vs
91 mmol/mol]; P < 0.001), higher FBG levels (10.4 vs
8.8 mmol/L [187 vs 159 mg/dL; P < 0.001), and had fewer
participants (94 vs 98%; P = 0.006) who used OAMs tar-
geting PPG than nonresponders. Overall, both responders
and nonresponders at 24 weeks had a baseline mean dur-
ation of T2DM of 10 years and were generally Caucasian
(71 vs 58%), less than 65 years of age (75 vs 76%), and
overweight or obese (mean body mass index [BMI] for
both, 31 kg/m2) at baseline.
Glycemic response and insulin dose
Early response at 12 weeks was a strong predictor of subse-
quent response at 24 weeks as shown by the high sensitivity
(85.9%) and predictive positive value (91.4%) (Table 3). Re-
sponders at 24 weeks had significantly greater reductions
from baseline in adjusted mean (SE) HbA1c (− 2.2% [0.04]
vs − 0.8% [0.06]; − 24 [0.44] vs − 9 [0.66] mmol/mol;
P < 0.001) than nonresponders (Table 4), as to be ex-
pected per the definition of response. Responders com-
pared with nonresponders also had significantly greater
reductions from baseline in both adjusted mean (SE) daily
FBG (− 4.0 [0.09] vs − 3.3 [0.16] mmol/L; − 71 [1.6] vs − 59 [2.8] mg/dL; P < 0.001) and daily PPG (− 4.1 [0.11]
vs − 3.0 [0.18] mmol/L; − 73 [1.9] vs − 54 [3.3] mg/dL;
P < 0.001) (Table 4). The difference between responders
and nonresponders in change from baseline adjusted
mean daily BG levels at 24 weeks was small at pre-
breakfast and 3 AM, but more pronounced at other time
points (Fig. 1). More responders than nonresponders (39%
vs 34%) reached FBG target ≤ 5.6 mmol/L (≤ 100 mg/dL)
at 24 weeks (Fig. 2). Responders were also more likely to
reach PPG target ≤ 10.0 mmol/L (≤ 180 mg/dL) after
breakfast (77% vs 69%), lunch (81% vs 66%), and evening
meal (79% vs 71%) than nonresponders (Fig. 2). (Note: the
PPG target was defined for this analysis and was not given
to investigators during these trials.) The adjusted mean
Table 1 Number of responders and nonresponders to insulin











(HbA1c ≥ 7% and
< 1% reduction)
n (%)
Yes Yes 595 (50) –
Yes No 88 (7) –
No Yes 505 (43) –
No No 297 (20)
Total (N = 1485) 1188 (80) 297 (20)
Abbreviation: HbA1c glycated hemoglobin
Table 2 Baseline characteristics of responders and
nonresponders to insulin glargine 100 Units/mL at 24 weeks
Responders at
24 weeks









Age, years 57.8 (9.9) 57.2 (10.1) 0.323
Age group 0.833
< 65 years 893 (75.2) 225 (75.8)
≥ 65 years 295 (24.8) 72 (24.2)
Gender 0.012
Women 543 (45.7) 160 (53.9)
Men 645 (54.3) 137 (46.1)
Duration of T2DM, years 10.3 (6.6) 9.7 (6.5) 0.159
Weight, kg 87.5 (19.7) 85.8 (21.6) 0.201
BMI, kg/m2 31.3 (5.70) 30.9 (5.70) 0.213
HbA1c, % 9.1 (1.2) 8.3 (0.9) < 0.001
HbA1c, mmol/mol 99 (13) 91 (10) < 0.001
FBG, mg/dL 186.7 (52.0) 158.5 (42.2) < 0.001
≥ 1 OAMs Targeting PPGa 1111 (93.5) 290 (97.6) 0.006
SU, yes 1067 (89.8) 284 (95.6) 0.002
2 OAMs 790 (66.5) 194 (65.3) 0.701
MET/SU 614 (51.7) 167 (56.2) –
3 OAMs 389 (32.7) 100 (33.7) 0.761
MET/SU/TZD 346 (29.1) 89 (30.0) –
4 OAMs 7 (0.6) 3 (1.0) 0.429
Individual participant data were pooled from 3 randomized clinical trials [20–22]
and are mean (SD) or n (%). Patients are those who were randomized to insulin
glargine as the only insulin treatment and with no missing HbA1c values at
24 weeks. Two-sided P values were considered statistically significant if < 0.05
and were calculated by ANOVA model (response = subgroup) for continuous vari-
ables and by Pearson’s Chi-square or Fisher’s exact (for OAM data with less than
80% of cells with an expected value ≥5) test for categorical variables. Abbrevia-
tions: AGI alpha glucosidase inhibitor, BMI body mass index, DPP-IV dipeptidyl
peptidase IV, FBG fasting blood glucose, HbA1c glycated hemoglobin, MEGmegli-
tinides, MET metformin, OAM oral antihyperglycemic medication, PPG postpran-
dial blood glucose, SD standard deviation, SU sulphonylurea, T2DM type 2
diabetes mellitus, TZD thiazolidinedione. aOAMs targeting postprandial glucose
were SU, DPP-IV, AGI, and MEG
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(SE) daily IGlar dose was similar between responders and
nonresponders at 24 weeks (45.2 [1.4] vs 42.2 [2.3] units/
day; 0.49 [0.01] vs 0.47 [0.02] units/kg/day) (Table 4).
From a post hoc graphical assessment (data not shown),
inverse linear relationships were observed between im-
provements in glycemic measures (FBG, daily mean PPG,
HbA1c) and baseline HbA1c or FBG which confirm the
findings mentioned above. Plots of improvements in gly-
cemic measures and insulin dose (data not shown) did not
reveal an informative pattern.
Hypoglycemia
At 24 weeks, responders compared with nonresponders
had a significantly higher incidence of total (82.5 vs
70.4%; P < 0.001), nocturnal (60.3 vs 50.5%; P = 0.002) and
documented symptomatic (65.8 vs 55.6%; P < 0.001)
hypoglycemia and significantly higher adjusted mean
1-year event rates of total (20.3 vs 14.7; P = 0.004) and
documented symptomatic (9.7 vs 7.1; P = 0.022)
hypoglycemia (Fig. 3). Nocturnal hypoglycemia adjusted
mean 1-year event rates (5.4 vs 5.0; P = 0.608) and severe
hypoglycemia incidence (12 [1.0%] vs 0; P = 0.082) and ad-
justed mean 1-year event rates (0 for both; P = 1.000) were
similar between groups. From a post hoc graphical assess-
ment (data not shown), no meaningful pattern between
hypoglycemia rate and insulin dose was revealed.
Discussion
This analysis showed that the composite HbA1c re-
sponse at 12 weeks was a strong predictor of maintain-
ing at least the same HbA1c response (composite) at
24 weeks. Responders had higher HbA1c and FBG levels
at baseline with fewer participants using OAMs target-
ing PPG than nonresponders. Responders compared
with nonresponders were also more likely to reach target
FBG ≤ 5.6 mmol/L (≤ 100 mg/dL) and hypothetical tar-
get PPG ≤ 10.0 mmol/L (≤ 180 mg/dL) at 24 weeks with
similar IGlar doses. Moreover, adjusted mean IGlar
doses at 24 weeks for both groups were still below the
limit for basal insulin titration (> 0.5 units/kg/day) rec-
ommended by the American Diabetes Association and
European Association for the Study of Diabetes [1].
Despite the relatively high averages for IGlar dose and
hypoglycemia incidence and yearly event rates at
24 weeks, hypoglycemia incidence and yearly event rates
were lower in nonresponders than responders, and both
groups had similar yearly event rates of nocturnal
hypoglycemia. Given that hypoglycemia data were col-
lected systematically, the chance for under-estimation of
hypoglycemia incidence is expected to be small. The
high incidence of hypoglycemia in both groups may be
explained in part by the aggressive dose-titration proto-
cols used in these trials (Additional file 1), and therefore
inadequate titration is unlikely to have caused a lower
incidence of hypoglycemia in nonresponders. The mean
IGlar dose was close to 0.5 units/kg. Scatter plots of
HbA1c versus dose and hypoglycemia yearly event rate
versus dose at 24 weeks did not show an informative
pattern to suggest a relationship between dose and im-
provement in glycemic control or lower hypoglycemia
incidence. Some people with T2DM, however, may need
greater than 0.5 units/kg/day of basal insulin in case of
higher insulin resistance. The first-up-titrate-basal insu-
lin approach is expected to be useful in some patients
and should be considered on an individual basis. Early
introduction of a medication for the control of PPG to
reduce the risk of hypoglycemia, especially if using a
GLP1-RA, could also benefit some individuals. For non-
responders to IGlar who have reached FBG target or
whose up-titration of IGlar dose is limited by the fre-
quency and/or severity of hypoglycemia, diabetes treat-
ment should be intensified with PPG-lowering agents,
such as prandial insulin or GLP1-RA.
Our findings are consistent with several post hoc ana-
lyses of trials assessing differences between responders
and nonresponders to basal insulin treatment. Scheen et
al. [13] evaluated the relative contributions of FBG and
PPG to overall hyperglycemia in insulin-naive partici-
pants who either reached or did not reach target HbA1c
< 53 mmol/mol (< 7%) with IGlar or insulin lispro mix
25 at 24 weeks in the DURABLE trial. Insulin doses
were higher but hypoglycemia yearly event rates were
lower in nonresponders compared with responders at
study endpoint. Failure to reach target FBG ≤ 5.
6 mmol/L (≤ 100 mg/dL) was the primary reason for not
achieving target HbA1c in both insulin groups, suggesting
the need to first up titrate basal insulin before intensifying
therapy with PPG-lowering agents. Similarly, Khunti et al.
Table 3 Prediction of insulin glargine 100 Units/mL response at
24 weeks based on early response at 12 weeks
Responders at week 24
Yes No
Responders at Week 12 Yes 91% 9%
No 46% 54%
Predictive parameters
Odds ratio = 12.7 (P < 0.001)
Sensitivity = 85.9%
Specificity = 67.7%
Positive predictive value = 91.4%
Negative predictive value = 54.5%
Sensitivity is the percentage of subsequent responders (HbA1c <7% or ≥ 1%
reduction) correctly identified (true-positive rate). Specificity is the percentage
of subsequent nonresponders (HbA1c ≥7% and < 1% reduction) correctly
identified (true-negative rate). Positive predictive value is the percentage of
subsequent responders among early responders. Negative predictive value is
the percentage of subsequent nonresponders among early nonresponders.
Abbreviation: HbA1c glycated hemoglobin
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Table 4 Glycemic response and insulin dose in responders and nonresponders to insulin glargine 100 Units/mL at 24 weeks
Responders
(HbA1c < 7% or ≥ 1% reduction)
Nonresponders
(HbA1c ≥ 7% and < 1% reduction)
HbA1c (mmol/mol), n 1188 297
Endpoint 74 (0.44) 89 (0.66)
CFB − 24 (0.44) − 9 (0.66)
CFB, LSM Diff (95% CI) − 15 (− 16.40, − 13.88); P < 0.001
HbA1c (%), n 1188 297
Endpoint 6.76 (0.04) 8.14 (0.06)
CFB − 2.16 (0.04) − 0.78 (0.06)
CFB, LSM Diff (95% CI) − 1.38 (− 1.50, − 1.27); P < 0.001
Dose (units/day), n 1187 297
Endpoint 45.21 (1.36) 42.16 (2.29)
LSM Diff (95% CI) 3.05 (− 1.24, 7.34); P = 0.164
Dose (units/kg/day), n 1187 297
Endpoint 0.49 (0.01) 0.47 (0.02)
LSM Diff (95% CI) 0.02 (− 0.02, 0.07); P = 0.272
Fasting blood glucose, n 692 143
Endpoint (mmol/L) 6.13 (0.09) 6.83 (0.16)
CFB − 3.97 (0.09) − 3.26 (0.16)
CFB, LSM Diff (95% CI) − 0.71 (− 1.00, − 0.41); P < 0.001
Endpoint (mg/dL) 110.39 (1.63) 123.10 (2.81)
CFB − 71.48 (1.63) − 58.77 (2.81)
CFB, LSM Diff (95% CI) −12.71 (− 18.00, − 7.42); P < 0.001
Daily mean SMBG, n 640 128
Endpoint (mmol/L) 7.30 (0.09) 8.20 (0.16)
CFB − 3.85 (0.09) − 2.95 (0.16)
CFB, LSM Diff (95% CI) − 0.90 (− 1.20, − 0.60); P < 0.001
Endpoint (mg/dL) 131.45 (1.62) 147.70 (2.83)
CFB − 69.33 (1.62) − 53.08 (2.83)
CFB, LSM Diff (95% CI) − 16.25 (− 21.60, − 10.89); P < 0.001
Daily mean premeal SMBG, n 678 142
Endpoint (mmol/L) 6.59 (0.08) 7.51 (0.14)
CFB − 3.70 (0.08) − 2.78 (0.14)
CFB, LSM Diff (95% CI) − 0.92 (− 1.19, − 0.65); P < 0.001
Endpoint (mg/dL) 118.75 (1.52) 135.30 (2.58)
CFB − 66.64 (1.52) − 50.09 (2.58)
CFB, LSM Diff (95% CI) − 16.55 (− 21.40, − 11.69); P < 0.001
Daily mean postprandial SMBG, n 677 139
Endpoint (mmol/L) 8.31 (0.11) 9.32 (0.18)
CFB − 4.03 (0.11) − 3.02 (0.18)
CFB, LSM Diff (95% CI) − 1.01 (− 1.36, − 0.66); P < 0.001
Endpoint (mg/dL) 149.70 (1.93) 167.91 (3.33)
CFB − 72.70 (1.93) − 54.49 (3.33)
CFB, LSM Diff (95% CI) − 18.21 (− 24.50, − 11.93); P < 0.001
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[14] found that the suboptimally controlled group (HbA1c
≥ 53 mmol/mol [7%]) treated with once-daily insulin dete-
mir in the SOLVE trial had a relatively low risk of
hypoglycemia and suboptimal FBG levels at 24 weeks,
which according to the authors suggested that ‘a more
aggressive titration regimen could be implemented to im-
prove glycemic control’. A Spanish cross-sectional study
looking at people with T2DM on basal insulin also showed
that approximately half of the participants had high FBG
and HbA1c levels, and hence for those participants, fur-
ther adjustments of basal insulin would be necessary
[15]. Similar patterns of response to basal insulin were
observed in a recent meta-analysis of participant-level
data from 3415 insulin-naïve participants treated with
IGlar in 16 randomized, treat-to-target trials [23].
Participants who reached target HbA1c < 53 mmol/mol
(< 7%) at 24 weeks were more likely to achieve target
FBG ≤ 5.5 mmol/L (≤ 100 mg/dL), as well as had
greater likelihood of reaching target FBG levels
without hypoglycemia. Nevertheless, responders had more
hypoglycemia events than participants with HbA1c levels of
53 mmol/mol (7%) to 64 mmol/mol (8%) or > 64 mmol/mol
(8%). The higher HbA1c groups also had more weight gain
and a slightly greater insulin dose at 24 weeks. Interest-
ingly, more frequent hypoglycemia was associated with
lower baseline C-peptide levels and was associated with
Table 4 Glycemic response and insulin dose in responders and nonresponders to insulin glargine 100 Units/mL at 24 weeks
(Continued)
Responders
(HbA1c < 7% or ≥ 1% reduction)
Nonresponders
(HbA1c ≥ 7% and < 1% reduction)
Intrapatient between-day SMBG variability, n 673 137
Endpoint (mmol/L) 0.62 (0.03) 0.71 (0.05)
CFB − 0.27 (0.03) − 0.18 (0.05)
CFB, LSM Diff (95% CI) − 0.08 (− 0.18, 0.01); P = 0.070
Endpoint (mg/dL) 11.20 (0.52) 12.74 (0.89)
CFB − 4.86 (0.52) − 3.33 (0.89)
CFB, LSM Diff (95% CI) − 1.53 (− 3.19, 0.13); P = 0.070
Endpoints and CFB values are expressed as LSM (SE) unless otherwise stated. Pearson’s Chi-square test was used for categorical variables and ANCOVA model
(response = baseline of the response variable + responder + study + study-by-responder interaction + sulphonylurea use [yes/no]) for continuous variables.
P values are based on fixed effects meta-regression with a 2-sided α-level of 0.05. Heterogeneity was assessed by study-by-responder interaction. P values for
interaction were nonsignificant (≥ 0.05) for outcomes presented with the exception of fasting blood glucose (P = 0.012), indicating results in these trials were
relatively homogeneous. All patients had HbA1c values at 24 weeks and received insulin glargine as the only insulin therapy. Abbreviations: CFB change from
baseline, CI confidence interval, Diff difference, HbA1c glycated hemoglobin, LSM least squares mean, SE standard error, SMBG self-monitored blood glucose, T2DM
type 2 diabetes mellitus
Fig. 1 Blood glucose over time in responders and nonresponders to insulin glargine 100 Units/mL at 24 Weeks. Blood glucose values for SMBG
time points are daily mean. Abbreviations: MCFB mean change from baseline, Pre-B before breakfast, Pre-L before lunch or midday meal, Pre-D
before dinner, Post-B 2 h after breakfast, Post-L 2 h after lunch or midday meal
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Fig. 2 Responders and nonresponders to insulin glargine 100 Units/mL at 24 weeks who reached blood glucose targets. Data are percentage of
responders and nonresponders who reached target fasting blood glucose (≤5.6 mmol/L; ≤100 mg/dL) (a) and target postprandial glucose (≤
180 mg/dL) after breakfast (b), lunch (c), and dinner (d). The postprandial glucose target was defined for this analysis and was not given to
investigators during these trials
Fig. 3 Hypoglycemia in responders and nonresponders to insulin glargine 100 Units/mL at 24 weeks. Data are incidence (a) and 1-year event
rates (b)
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more weight gain at 24 weeks in all HbA1c groups. The
authors concluded that people initiating therapy with
IGlar are a heterogeneous group in terms of glycemic re-
sponse and hypoglycemia risk. Our analysis focused on
glycemic response, and therefore did not include weight
changes from baseline. Baseline C-peptide values were not
available to assess.
Studies analyzing the predictability of early response
to IGlar for subsequent longer-term response are lim-
ited. The high predictive values of 12-week response
for subsequent treatment success at 24 weeks in our
meta-analysis are consistent with results of a pooled
analysis of participant-level data by Fu et al. [17]
using the same composite HbA1c endpoint to meas-
ure response to IGlar and to OAMs in 3 randomized
clinical trials. The high predictive values of 12-week
response in both analyses support current guidelines
that recommend clinicians evaluate therapeutic re-
sponses to pharmacologic interventions 12 weeks after
initiating therapy [1].
Participants with higher baseline HbA1c levels
have been shown to be less likely to achieve target
HbA1c < 53 mmol/mol (< 7%) with basal insulin therapy in
randomized clinical trials [13, 16] and in observational stud-
ies [14]. Other baseline factors associated with not achieving
this HbA1c target include longer duration of diabetes [14,
16], use of a sulphonylurea [16], number of OAMs and lon-
ger duration of OAM treatment [14], and higher BMI [14].
When achievement of HbA1c < 53 mmol/mol (< 7%) was
further analysed by reaching target FBG < 7.2 mmol/L
(< 130 mg/dL) in an observational cross-sectional study
of 9899 participants with T2DM [15], only 18% of the
study population achieved both HbA1c and FBG targets.
Of the participants who did not reach HbA1c target
(75% of the total population), those who reached tar-
get FBG (24%) were older, had a longer duration of
diabetes, and had lower mean values for HbA1c, BMI,
diastolic blood pressure, and low-density lipoprotein
cholesterol at baseline than those who did not reach
target FBG (51%).
Limitations of this meta-analysis are in part due to its
post hoc design, and therefore a cause and effect rela-
tionship cannot be established. Additionally, data are
from randomized clinical trials, thereby results may not
reflect what would be seen in a real-world setting, where
more aggressive titration of basal insulin is possible and
the addition of prandial insulin or a GLP1-RA is an
option. Additionally, a lesser reduction in HbA1c (e.g.,
8.7 mmol/mol [0.8%] vs 11 mmol/mol [1%]) despite not
reaching target HbA1c < 53 mmol/mol [< 7%] could
be considered clinically significant. Reasons for not
increasing IGlar dose to reach HbA1c goal, particu-
larly for participants without hypoglycemia, were not
assessed in these trials, and insulin resistance was not
measured. Treatment algorithms and noninsulin treat-
ment options have also changed since these studies
were conducted, and therefore results of our analysis
may not fully reflect today’s clinical practice.
Conclusions
As would be expected, more participants with clinic-
ally meaningful reductions in HbA1c were identified
in this analysis by expanding the definition of re-
sponse to include a ≥ 11 mmol/mol (≥ 1%) reduction
in HbA1c from baseline. Baseline HbA1c and FBG
were also statistically higher in responders than non-
responders, although there was not a significant clin-
ical difference to warrant a cut-off for basal insulin
administration. At both 12 and 24 weeks, the majority
of responders and nonresponders had not reached
target FBG, suggesting that more aggressive insulin
titration was still possible in responders who had not
yet reached FBG and HbA1c goals, assuming hyper-
or hypoglycemia at other self-monitoring BG time
points were not the driving factors. These findings,
coupled with the high predictability of 12-week re-
sponse for subsequent longer-term response, suggest
that the composite HbA1c endpoint is superior to the
single HbA1c measure. Clinicians should consider the
magnitude of reduction in HbA1c at 12 weeks in
addition to achievement of target HbA1c to better
recognize the potential for success with this effective
starter basal insulin, especially for people with more
advanced T2DM and/or higher HbA1c levels, which
may require larger insulin doses to obtain glycemic
control possibly related to higher insulin resistance.
Moreover, sequentially targeting FBG and PPG levels
could identify nonresponders to IGlar who could be-
come responders with additional therapy beyond basal
insulin. This approach could be encouraging to
people with T2DM who are clinically benefiting early
from IGlar therapy to continue treatment to get
closer to desired goal. A better understanding of con-
cerns of clinicians and/or people with T2DM and rea-
sons for not up titrating or intensifying IGlar therapy
is needed and is currently being assessed in a large
observational study [24–26]. Studies evaluating the
value of adding basal-only versus basal-bolus insulin
or GLP1-RA treatment in people with T2DM not
adequately controlled on current noninsulin combin-
ation therapies are needed to inform clinicians’ treat-
ment selection.
Our findings confirm the clinical utility of IGlar as a
safe and effective starter basal insulin and offer insights
about addressing an individual’s response to treatment
as early as 12 weeks. Timely adjustments to basal insulin
therapy could help keep people with T2DM on track to
benefit from better glycemic control.
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